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Summary Epidermal growth factor (EGF) receptor-overexpression is characteristic of many human tumours of epithelial origin and has been
correlated with unfavourable patient prognosis. Its involvement in the malignant process, its elevated expression in tumours and its
accessibility on the tumour cell surface make the EGF receptor a potential target for directed tumour therapy. We have previously
characterized a recombinant antibody- Pseudomonasexotoxin Afusion protein, scFv(225)-ETA, which displayes antitumoral activitytowards
EGF receptor-overexpressing tumour cells but is less potent in tumour cell killing than TGF-a-ETA, a recombinant toxin using the natural EGF
receptor ligand transforming growth factor a (TGF-a) as a targeting domain. Here, we describe the construction and functional
characterization in vitro of a novel single-chain antibody-toxin, scFv(14E1)-ETA, based on the independently isolated EGF receptor-specific
monoclonal antibody 14E1. ScFv(14E1)-ETA binds to an EGF receptor epitope that is very similar or identical to that of scFv(225)-ETA with
nine times higher affinity than the latter and displays more than tenfold higher cytotoxic activity on EGF receptor-overexpressing tumour cells.
ScFv(14E1)-ETA cell killing activity was very similar to that of TGF-a-ETA on receptor-overexpressing cells but, in contrast to the latter,
scFv(14E1)-ETA was much more selective and did not display significant cytotoxic activity on cells expressing moderate EGF receptor levels.
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The erbB/EGF receptor-related gene family encodes growth factor
receptors with intrinsic tyrosine kinase activity. Four members of
this family have been identified: ErbBlEGF receptor, ErbB-2,
ErbB-3 and ErbB-4 (Peles and Yarden, 1993). Members of this
family have been implicated in the development of a variety of
human malignancies. EGF receptor gene amplification and over-
expression have been observed in a high percentage of primary
human carcinomas ofepithelial origin, including glioblastoma and
cancer of the lung, breast, head and neck and bladder, and corre-
lates with an unfavourable prognosis for the patients (Gullick,
1991). Increased receptor expression in tumour cells is often
accompanied by increased production of TGF-a (Derynck et al,
1987; Van de Vijveret al, 1991), which leads to receptor activation
by an autocrine pathway and contributes to malignant transforma-
tion. Because ofits accessibility on the cell surface, its overexpres-
sion in several types ofcancer and its involvement as a marker for
an unfavourable prognosis, the EGF receptor is under intensive
scrutiny as a therapeutic target for novel anti-tumour reagents.
Various strategies have been used to target the EGF receptor for
tumour therapy. Monoclonal antibodies directed towards the extra-
cellular domain of the EGF receptor have proven effective in the
inhibition oftumour cell growth. The EGF receptor-specific mono-
clonal antibody (MAb) 225 competes with EGF for binding to the
EGF receptor, thereby blocking ligand-dependent receptor activa-
tion (Fan etal, 1993a). Treatment with MAb 225 inhibits the growth
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of EGF receptor-expressing tumour cells in vitro and in animal
models in vivo (Masui et al, 1984; Ennis et al, 1989). In an attempt
to achieve more potent antitumoral effects, recombinant fusion
proteins have been constructed that contain the enzymatic domains
ofPseudomonas exotoxin A (Chaudhary et al, 1987) or diphtheria
toxin (Shaw et al, 1991) and use the natural EGF receptor ligands
TGF-a or EGF for targeting to receptor-overexpressing tumour
cells. Because ofthe growth factor domain, such toxins are able to
activate the EGF receptor (Schmidt and Wels, 1996), which might
facilitate rapid uptake by tumour cells but could also be responsible
for the significant cytotoxic activity displayed on cells expressing
only moderate levels ofthe target receptor.
As an alternative to growth factors, recombinant single-chain
(sc) Fv domains consisting of the variable regions of the heavy
and light chains of receptor-specific antibodies can be used
for the target cell-specific delivery of therapeutic effector func-
tions. We have recently described a recombinant single-chain
antibody-toxin consisting of a scFv domain derived from the
antagonistic MAb 225 and truncated Pseudomonas exotoxin A
(Wels et al, 1995). This scFv(225)-ETA fusion toxin displays high
selectivity for EGF receptor-overexpressing tumour cells and
inhibits their growth in vitro and in animal models in vivo. Like
the parental antibody, scFv(225)-ETA is unable to activate the
EGF receptor but competes with EGF for receptor binding (Beerli
et al, 1994; Wels et al, 1995).
Here we describe the construction, bacterial expression and in
vitro characterization ofscFv(14E1)-ETA, a novel EGF receptor-
specific single-chain antibody-toxin. This independently isolated
fusion protein is very similar in its structure and target cell selec-
tivity to the previously described scFv(225)-ETA but is more than
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MATERIALS AND METHODS
Cell lines
The SKBR3 and MDA-MB468 human breast tumour cell lines,
the A431 human epidermoid tumour cell line and the NE1 mouse
fibroblast cell line were maintained in Dulbecco's modified Eagle
medium containing 8% heat-inactivated fetal calf serum.
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Figure 1 (A) Schematic representation of the recombinant single-chain
antibody toxins scFv(14E1)-ETA and scFv(225)-ETA and the growth factor
toxin TGF-a-ETA. The bacterially expressed scFv-ETA proteins consist of
the scFv domains of the monoclonal antibodies 225 or 14E1 containing the
heavy-chain (VH) and light-chain (VL) variable domains fused to amino acids
252 to 613 of Pseudomonas exotoxin- A (ETA) representing the translocation
domain 11, domain lb and domain IlIl which mediates the ADP ribosylation of
the eukaryotic elongation factor 2. TGF-a-ETA contains amino acids 1 to 50
of human TGF-a as an EGF receptor-specific binding domain. Included in the
molecules are the synthetic FLAG epitope and a cluster of 6 histidine
residues at the N-terminus and another cluster of six histidine residues
N-terminal of ETA domain 11 facilitating the purification of the proteins via Ni2+
affinity chromatography (not shown). (B) SDS-PAGE analysis of recombinant
toxins purified from E. colilysates. The proteins were expressed in E. coli
CC 18, purified via binding of the histidine clusters included in the molecules
to a Ni2+ column and analysed by SDS-PAGE and Coomassie staining.
The positions of the 67-kDa scFv(225)-ETA (lane 2) and scFv(14E1)-ETA
(lane 3) and the 47-kDa TGF-a-ETA (lane 1) proteins are indicated. M,
molecular weight standards
ten times more potent in in vitro cell killing activity than the latter
and is similar to a growth factor toxin containing TGF-a.
However, in contrast to the TGF-a toxin, scFv(14E1) is highly
specific for tumour cells overexpressing the EGF receptor.
Preparation of the 14E1 hybridoma
The hybridoma cell line 14E1 was prepared at Triton Diagnostics
(Alameda, CA, USA) by fusing splenocytes from mice immunized
with A431 cells to the non-secreting mouse myeloma cell line
SP2/0-Agl4 (both from ATCC, Rockville, MD, USA) according
to the method ofKohler and Milstein (1975). Briefly, Balb/c mice
were intraperitoneally immunized with 107 A431 cells emulsified
in an equal volume of RIBI adjuvant (RIBI Immunochem
Research, Hamilton, MT, USA) and boosted every 2 weeks. Sera
were collected and tested biweekly by ELISA for reactivity
against A431 cell lysate and the extracellular portion of the EGF
receptor purified from A431 cell-conditioned media (Weber et al,
1984). Mice with positive titres were intravenously boosted with
antigen in phosphate-buffered saline (PBS) and sacrificed 4 days
later. A 4:1 ratio ofsplenocytes to myeloma cells were fusedusing
a 50% polyethylene glycol solution and plated in 96 wells at a
density of 2.5 x 105 splenocytes per well in RPMI supplemented
with 0.1 mm hypoxanthine and 5.8 gM azaserine to select for
hybrids. Supernatants were screened by ELISA for EGF receptor
specificity; positive clones were isolated and put through two
additional rounds of subcloning. Antibodies were raised in ascites
and purified on protein G-agarose. Several EGF receptor-specific
clones were isolated; one ofthese, 14E1 (IgGI), which recognizes
the extracellular portion of the EGF receptor, was shown to
compete with EGF and TGF-a for receptor binding in radioligand
binding assays (data not shown).
Construction of scFv(14E1) and scFv(14E1)-ETA
14E1 hybridoma cell mRNA was isolated using a Quick Prep RNA
purification kit (Pharmacia Biotech, Brussels, Belgium). First-strand
cDNA synthesis was carried out according to the manufacturer's
recommendations using a cDNA synthesis kit (Stratagene,
Heidelberg, Germany) with 100ng of mRNA and random primers.
For amplification of the heavy-chain (VH) and light-chain (VL)
variable domains the first-strand cDNA served as a template in a
polymerase chain reaction (PCR) as described (Wels et al, 1992a).
For amplification of the VH domain, 50 pmol each of the
oligonucleotides 5'-AGGTSMARCTGCAGSAGTCWGG-3' and
5'TGAGGAGACGGT GACCGTGGTCCCTTGGCCCC-3' were
used for amplification of the VL kappa domain, 50 pmol each
of the oligonucleotides 5'-GCGACCITGCACGCGTAGACAT-
TGAGCTCACCCAGTCTCCA-3' and 5'-CGCTACAATAGCG-
GCCGCTACCGTCCGTlTGATTrCCAGCTTGGTGCC-3' or
5'-CGCTACATTAGCGGCCGCTACCGTCCGTTTCAGCTC-
CAGCTTGGTCCC-3' wereused(M =A+C, R=A+G, S =C+G,
W = A + T, Y = C + T, K = G + T). Subsequently, the VH and
VL PCR products were reamplified using 50 pmol each of the
oligonucleotide primers 5'-TGAGGAGACGGTGACCGTGG-
TCCCTTGGCCCCAG-3' and 5'-ATTATAAGCTTCAG-
GTSMARCTGCAGSAGTCWGG-3' (VH) or
5'-TTAGATCTCTAGAAKCTCGAGYTTKGTSC-3' and 5'-
GACATTCAGCTGACCCAGWCTSC-3' (VL) respectively. PCR
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and XbaI (VL). MAb 14E1 VH cDNA was inserted into
HindlMI/BstEHl-digested plasmid pWW152 (Wels et al, 1995) which
contains a sequence encoding the 15 amino acid linker (GGGGS)3.
Subsequently, the 14E1 VL fragment was inserted 3' ofthe VH and
linker sequences, resulting in the scFv(14El)-encoding plasmid
pWW152-14EI. For bacterial expression, the scFv(14EI) sequence
was isolated as aHindIllIXbaI fragment frompWW152 and inserted
into HindlII/XbaI-digested plasmid pSW50 (Wels et al, 1995). For
the construction of the scFv(14El)-ETA toxin fusion, the
scFv(14EI) fragment was inserted into HindlII/XbaI-digested
plasmid pSW202 containing a truncated Pseudomonas ETA gene
thatlacks the original cell binding domain Taofthe toxin (Wels et al,
1995). The resulting plasmids pSW50-14EI and pSW202-14EI
encode, respectively, the scFv(14El) and scFv(14E1)-ETA proteins,
fused at the N-terminus to the ompA signal sequence, the synthetic
FLAG epitope and a cluster of six histidine residues, under the
control ofan IPTG inducible tac promoter.
Expression and purification of scFv and scFv-ETA
fusion proteins
Single colonies ofE. coli CC118 carrying plasmids pSW50-14El
or pSW50-225 for the expression of EGF receptor-specific scFv
proteins, or plasmids pSW202-14EI or pSW202-225 (Wels et al,
1995) forthe expression ofscFv-ETA fusionproteins, were grown
overnight at 370C in Luria broth (LB) medium supplemented with
0.6% glucose and 100 jg ml-' ampicillin. E. coli CC118 carrying
plasmid pSW202-TGF-a (Schmidt and Wels, 1996) were used for
the expression ofTGF-a-ETA, a recombinant growth factor toxin
that consists ofamino acids I to 50 ofhuman TGF-a fused to trun-
cated Pseudomonas ETA. The cultures were diluted 30-fold in the
same medium, grown at 370C to an OD550 of0.7 and induced with
0.1 mm isopropyl P-D-thiogalactopyranoside for 1 h at room
temperature. Cells were harvested by centrifugation at 10 000 g for
10 min at 4°C, the cell pellet from 11 of culture was resuspended
in 15 ml ofPBS containing 6 M guanidine hydrochloride and lysed
by sonication. Following incubation at room temperature for
30 min, the lysate was clarified by centrifugation at 30 000 g for
30 min at 4°C. The supematant was diluted to 3 M guanidine
hydrochloride with PBS and recombinant proteins were purified
via binding to Ni2+-saturated chelating sepharose (Pharmacia
Biotech). Specifically bound proteins were eluted with 3 M
guanidine hydrochloride, 250mm imidazole in PBS. Fractions
containing recombinant fusion proteins were pooled and dialysed
twice against PBS, 400 mM L-arginine and PBS. Typical yield of
purified proteins was 1 mg 1-1 of original bacterial culture with a
purity of approximately 70% determined by SDS-PAGE and
Coomassie brilliant blue staining.
ScFv-ETA binding assay
The binding of scFv-ETA proteins to the EGF receptor was
measured by ELISA as described (Schmidt et al, 1996). Ninety-
six-well microtitre plates coated with recombinant protein
comprising the extracellular domain of the human EGF receptor
were blocked with 3% bovine serum albumin (BSA) in Tris-
buffered saline (TBS) (10 mm Tris-HCl, pH 7.5, 150 mm sodium
chloride). Fifty microlitres ofscFv(225)-ETA or scFv(14El)-ETA
at concentrations ranging from 0.03 nm to 1 gM were added to the
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Figure 2 (A) Binding of scFv(14E1)-ETA and scFv(225)-ETA to recombinant
extracellular domain of the EGF receptor. Immobilized extracellular domain of
the EGF receptor was incubated with various concentrations of
scFv(14E1)-ETA (0) or scFv(225)-ETA (0). The amount
of specifically bound protein was measured, after incubation with rabbit
anti-ETA serum followed by alkaline phosphatase coupled anti-rabbit IgG
and conversion of the phosphatase substrate p-nitrophenylphosphate as the
absorbance at 405 nm. Each point was determined in triplicate. The standard
deviation is represented by error bars. (B) Inhibition of ligand-induced
activation of the EGF receptor by scFv(225)-ETA and scFv(14E1)-ETA. NE1
mouse fibroblasts expressing a human EGF receptor cDNA were grown in
low serum for 16 h and then treated with 10 ng ml-' EGF in the presence of
20 ,ug ml-' scFv(225)- ETA (lane 5) or scFv(14E1)-ETA (lane 6) or in the
absence of competitor (lane 2). Control cells were treated with PBS (lane 1)
or with 20 9g ml-1 scFv(225)-ETA (lane 3) or scFv(14E1)-ETA (lane 4)
without the addition of EGF. Equal amounts of cell lysates were analysed by
SDS-PAGE and immunoblotting with an anti-phosphotyrosine MAb, followed
by incubation with an anti-mouse horse radish peroxidase labelled antibody
and chemiluminescent detection (upper panel). The amount of EGF receptor
loaded in each lane was analysed by reincubation of the filter with 12E EGF
receptor-specific antiserum (lower panel). The position of the 170-kDa EGF
receptor is indicated (EGFR). M, molecular weight standards
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wells and the plates were incubated for 1 h at 37°C. Unbound
protein was removed, the wells were washed and incubated with
100g1 ofrabbit anti-exotoxin A serum for 1 h at 37°C followed by
incubation with 100 gl of goat anti-rabbit IgG coupled to alkaline
phosphatase (Sigma, St Louis, MO, USA). Specifically bound
scFv-ETA proteins were detected by incubation with a solution of
1 M Tris-HCl, pH 8.0, 1 mg ml p-nitrophenylphosphate disodium
(Sigma) for 30 min at room temperature; then the absorbance at
405 nm was measured.
Cell viability assay
The cell killing activity of ETA fusion proteins was measured
basically as described (Wels et al, 1992b). The cells were seeded in
96-well plates at a density of 1 x 104 cells per well in normal
growth medium. Various concentrations of ETA fusion proteins
were added to triplicate samples and the cells were incubated for
40 h. Ten microlitres of 10 mg ml-1 MTT (3-(4,5-dimethylthiazole-
2-yl)-2,5 diphenyltetrazolium bromide) (Sigma) in PBS was added
to each well and the cells were incubated for another 3 h. Cells
were lysed by the addition of 90 gl of 20% sodium dodecyl
sulphate (SDS) in 50% dimethyl formamide, pH 4.7. After solubil-
ization ofthe formazan product, the OD at 590 nm ofeach sample
was determined in a microplate reader (Dynatech, Denkendorf,
Germany) as a measure of the relative amount of viable cells in
comparison to cells grown without the addition of recombinant
proteins.
Competition experiments
Competition of TGF-ax-ETA binding by scFv proteins was
analysed in a cell viability assay as described above. SKBR3,
MDA-MB468 and A431 cells were incubated with 100 ng ml of
TGF-a-ETA alone or in the presence of 10gg ml-1 scFv(14E1) or
scFv(225) as competitors. After 40 h, cell viability was deter-
mined. Competition of scFv-ETA binding by the MAb 225
was analysed using A431 cells. The cells were incubated with
100 ng ml scFv(225)-ETA or scFv(14E1)-ETA with or without
the addition of a 100-fold molar excess of the EGF receptor-
specific MAb 225 as a competitor. After 40 h the relative number
ofviable cells was determined as described above.
Time course of scFv-ETA cell killing
A431 cells were seeded in 96-well plates at a density of 1 x 104
cells per well. After attachment of the cells, the medium was
removed and the cells were treated for various time intervals with
100 ng ml-1 of scFv-ETA proteins in normal growth medium. The
medium was removed, cells were washed twice with PBS and
grown for another 40 h in normal growth medium. Cell viability
was measured as described above.
Receptor activation assays
A431 human epidermoid carcinoma cells and NEI mouse fibro-
blasts expressing ahuman EGFreceptorcDNA (Beerli etal, 1994)
were grown for 16 h in DMEM supplemented with 0.5% fetal calf
serum (FCS). A431 cells were treated with purified recombinant
TGF-a-ETA at a concentration of 1 gg ml- with or without the
addition of 50 jg ml-1 scFv(14E1)-ETA or scFv(225)-ETA as
competitors. Control cells were treated with PBS or 20 ng ml-1
EGF. NEI cells were treated with EGF at a concentration of
10 ng ml-1 alone or in the presence of20gg ml-1 scFv(14El)-ETA
or scFv(225)-ETA. Control cells were incubated with PBS or with
scFv-ETA proteins in the absence of EGF. Following incubation
at 37'C for 10 min, the cells were lysed in a buffer containing
50 mm Tris-HCl, pH 8.0, 5 mm EGTA, 150 mm sodium chloride,
1 mM phenylmethylsulphonyl fluoride, 2 mm sodium vanadate,
50 mm sodium fluoride, 50 mm sodium molybdate, 1% Triton
X-100, 0.5% desoxycholate, 0.1% SDS. Extracts were clarified
by centrifugation at 10000 g for 10 min at 4°C. Cleared cell
lysates containing 15 ,ug each of total proteins were applied on a
7.5% SDS-PAGE. After electrophoresis, proteins were blotted on
a polyvinylidenedifluoride membrane (Millipore, Eschborn,
Germany) and phosphotyrosine-containing proteins were detected
by incubation ofthe membrane with an anti-phosphotyrosine MAb
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by
incubation with an anti-mouse horse radish peroxidase coupled
antibody and chemiluminescent detection with the enhanced
chemiluminescence (ECL) kit (Amersham, Aylesbury, UK).
RESULTS
Construction and bacterial expression of
scFv(14E1)-ETA
The 14E1 hybridoma producing a novel anti-EGF receptor mono-
clonal antibody (IgGI) was derived by immunization ofmice with
human A431 epidermoid carcinoma cells and fusion of spleno-
cytes following standard protocols. cDNAs encoding the heavy-
chain (VH) and light-chain (VL) variable domains of the 14E1
MAb were derived from 14E1 hybridoma cell mRNA by reverse
transcription and amplification using PCR. A single-chain Fv gene
was created by connecting VH and VL sequences via a synthetic
linker encoding the 15 amino acids (GGGGS)3, and the scFv gene
was fused to sequences encoding a truncated form of
Pseudomonas aeruginosa exotoxin A (ETA) in the pSW202
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Figure 3 Competition of the cytotoxic activity of scFv(225)-ETA and
scFv(14E1)-ETA by the monoclonal antibody 225. A431 human squamous
cell carcinoma cells were incubated for 40 h with 100 ng ml-' scFv(225)-ETA
(left) or scFv(14E1)-ETA (right) without the addition of competitor or in the
presence of a 100-fold molar excess of the EGF receptor-specific MAb 225
as a specific competitor or the isotype-matched control antibody FRP5 as
indicated. The relative number of viable cells was determined using an
enzymatic assay as described in Materials and methods. Each point was
determined in triplicate. The standard deviation is represented by error bars
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vector as described (Wels et al, 1995). The resulting expression
plasmid pSW202-14EI encodes, under the control of an IPTG
inducible tac promoter, a fusion protein consisting of the E. coli
ompA signal peptide at the N-terminus, followed by the synthetic
FLAG epitope, six histidine residues, the scFv(14EI), six histidine
residues and ETA amino acids 252-613. The structure of the
scFv(14E1)-ETA gene product is schematically shown in Figure
lA. The ETA portion of the molecule lacks the native cell binding
domain Ta of the toxin but contains the translocation domain II,
which is required for processing of the toxin and release into the
cytoplasm after internalization into target cells via the endosomal
route, and the enzymatic domain IIH, which catalyses the ADP-
ribosylation of eukaryotic elongation factor EF-2, thereby
arresting cellular protein synthesis (Ogata et al, 1992).
The scFv(14El)-ETA antibody-toxin and two previously
described recombinant toxins with specificity for the EGF
receptor, scFv(225)-ETA (Wels et al, 1995) and TGF-a-ETA
(Schmidt and Wels, 1996), were expressed in E. coli strain CCl 18.
Total bacterial lysates were prepared in 6 M guanidine hydrochlor-
ide, the lysates were diluted to 3 M guanidine hydrochloride and
the recombinant toxins were purified by binding to Ni2+-saturated
chelating sepharose and elution with 250 mm imidazole. Fractions
containing the recombinant scFv-ETA proteins were pooled,
imidazole and denaturant were removed by dialysis and the
proteins were concentrated by ultrafiltration. SDS-PAGE analysis
ofthe purified material revealed a purity of greater than 70% after
a single round of Ni2+ affinity purification (Figure iB). Likewise,
scFv(14EI) and scFv(225) proteins which lack the C-terminal
toxin domain were expressed and purified (data not shown). The
yield ofpurified recombinant proteins from 11 ofbacterial culture
was typically 1 mg of scFv-ETA proteins, 2 mg of TGF-a-ETA
and 0.5 mg of scFv proteins.
Binding properties of scFv(14E1)-ETA
ELISA experiments were performed to determine the binding of
scFv(14EI) to the EGF receptor. ScFv(14E1)-ETA at concentra-
tions ranging from 0.03 nm to 1 JM was added to the wells of 96-
well plates coated with purified recombinant extracellular domain
ofthe EGF receptor, the plates were incubated at 37°C for 1 h and
specifically bound protein was determined. The similar
scFv(225)-ETA molecule was used as a control. The results are
shown in Figure 2A. Both proteins, scFv(14E1)-ETA and
scFv(225)-ETA, specifically bound to the extracellular portion of
the EGF receptor in a saturable fashion. The apparent binding
affinity ofthe scFv(14E1)-ETA to EGF receptor, calculated as the
half-maximal saturation value, was 1 nm. The apparent binding
affinity ofscFv(225)-ETA to EGF receptor was much lower with a
half-maximal saturation value of 9 nm. Previously, an apparent
affinity of 12 nm was detenmined for scFv(225)-ETA in a similar
ELISA experiment with immobilized A431 cells as antigen (Wels
et al, 1995).
The parental MAb 225, as well as proteolytic and recombinant
fragments derived thereof, compete the binding ofEGFto the EGF
receptor, thereby inhibiting receptor activation (Fan et al, 1993b;
Beerli et al, 1994; Wels et al, 1995). In order to test whether the
scFv(14E1) domain can also block the binding of EGF, competi-
tion experiments were performed. NET murine fibroblasts
expressing human EGF receptor cDNA (Beerli et al, 1994) were
treated for 10 min at 37°C with 10 ng ml-' EGF with or without the
addition of 20 ug ml-' of scFv(14E1)-ETA or scFv(225)-ETA as
competitors. Control cells were treated with PBS or scFv-ETA
proteins in the absence ofEGF. Equal amounts ofcell lysates were
assayed for their phosphotyrosine content by SDS-PAGE and
subsequent immunoblotting with a specific anti-phosphotyrosine
antibody. The results are shown in Figure 2B. Treatment of cells
with EGF (lane 2) led to a strong increase in the phosphotyrosine
content of a protein corresponding in size with the 170-kDa EGF
receptor, which was confirmed by reprobing the filter with an anti-
EGF receptor serum (Figure 2B, lower panel). This EGF-induced
activation of the receptor was blocked to a great extent by
scFv(225)-ETA (lane 5), whereas scFv(14E1)-ETA completely
abolished receptor activation (lane 6). PBS and scFv-ETA proteins
alone had no effect on the phosphotyrosine content ofthe receptor
(lanes 1, 3 and 4). The results show that the recombinant
scFv(14E1)-ETA similar to scFv(225)-ETA is able to block EGF-
induced receptor activation but is much more potent than the latter
at identical concentrations.
In vitro cytotoxic activity and specificity of
scFv(14E1 -ETA
Both antibody-toxins, scFv(14E1)-ETA and scFv(225)-ETA,
inhibit the activation of EGF receptor by EGF, possibly via
binding to the same or very similar epitopes on the receptor. In
order to analyse the potential of MAb 225 to interfere with
scFv(14E1)-ETA binding, cell killing experiments were carried
out. The cytotoxic activity of scFv(14E1)-ETA was tested on
A431 cells using an enzymatic assay (Wels et al, 1992b). The
cells were incubated for 40 h with 100 ng ml-l (1.5 nM) of
scFv(14E1)-ETA or scFv(225)-ETA in the absence or presence of
a 100-fold molar excess of MAb 225, and cell viability was
measured in comparison to PBS-treated cells. The isotype-
matched ErbB-2-specific MAb FRP5 (Harwerth et al, 1992) was
included as a control. The results are shown in Figure 3. At the
concentration used, both antibody-toxins displayed similar cell
killing activity; approximately 90% and 86% of the cells were
killed by scFv(14E1)-ETA (Figure 3, right) and scFv(225)-ETA
(Figure 3, left) respectively. In the presence of an excess of the
specific competitor, MAb 225, the cytotoxic activity was reduced
in both cases. No cell killing was observed in the case of
scFv(225)-ETA; approximately 33% ofthe cells were killed in the
case ofscFv(14E1). An excess ofthe non-specific MAb FRP5 had
no effect on the cytotoxic activity of the scFv-ETA proteins. The
results show that the cytotoxic activity of scFv(14E1)-ETA is
specifically targeted to the EGF receptor, as cell killing can be
competed by the EGFreceptor-specific MAb 225. The results also
show that MAb 225 and the independently isolated 14E1 bind to
the same or very similar epitopes on the EGF receptor.
In vitro cell killing activity of recombinant toxins
specific for the EGF receptor
We have previously described the cytotoxic activity of
scFv(225)-ETA on several human tumour cell lines expressing
various amounts of the EGF receptor (Wels et al, 1995). As
scFv(14El)-ETA displays a significantly higher affinity for the
EGF receptor, cell killing experiments were performed to investi-
gate whethertheincreased affinity results in enhancedcytotoxicity
towards EGF receptor-expressing cells. In addition, TGF-a-ETA
was included in the experiment, a recombinant fusion toxin that
uses the natural EGF receptor ligand TGF-a as a cell-targeting
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Figure 4 In vitro cell killing activity of scFv-ETA proteins and TGF-a-ETA. A431 human squamous cell carcinoma cells (A), MDA-MB468 (B) and SKBR3 (C)
human breast carcinoma cells were incubated for 40 h with the indicated concentrations of scFv(225)-ETA (0), scFv(14E1)-ETA (0) orTGF-a-ETA (C1). In
addition, SKBR3 cells were treated with the ErbB-2-specific scFv(FRP5)-ETA (A). The relative number of viable cells was determined as described in Figure 3
and Materials and methods. Each point represents the mean of a set of data determined in triplicate in three independent experiments
domain (Schmidt and Wels, 1996). The structure ofTGF-a-ETA,
which is schematically shown in Figure IA, is very similar to that
of the TGF-a-PE40 molecule previously characterized by others
(Siegall et al, 1989). The in vitro toxicity ofthe scFv(14E1)-ETA,
the scFv(225)-ETA and the TGF-a-ETA proteins was tested on
three human tumour cell lines. The A431 epidermoid and the
MDA-MB468 breast carcinoma cells express 1-2 million EGF
receptors per cell, whereas the SKBR3 breast carcinoma cells
express approximately 50-fold lower EGF receptor levels on their
surface (Wels et al, 1995).
The cells were incubated for 40 h with various concentrations
of the EGF receptor-specific scFv-ETA and TGF-a-ETA
proteins. As a control, the SKBR3 cells which overexpress ErbB-2
were also treated with the ErbB-2-specific antibody-toxin
scFv(FRP5)-ETA (Wels et al, 1992b). The relative number of
viable cells in comparison to untreated controls was determined
with an enzymatic assay (Wels et al, 1992b). The results are shown
in Figure 4. A431 cells were very sensitive to the toxins, with
scFv(14E1)-ETA and TGF-a-ETA showing similar activity (IC50
below 1 ng ml-') and scFv(225)-ETA being less potent at lower
British Journal ofCancer (1997) 75(11), 1575-1584
1580 M Schmidt etal
A
100.
B
A431
90
80.
70
60
50-
40.
301
20
-
2
c 0
0
0
0
a)
.G-
cJ
0)
1.C
a)
>, 0)
0.
CD
0)
c
0 cJ 0
0
a) 0 cm
a)
0 c 0
2 0 Is
0
0) .0
Cu
5
VPCancerResearchCampaign 1997EGFreceptor-specificantibody-toxin 1581
A431
9t'
EGFRIN.
A
Anu-pnospnotyrosine
A
scFv(FRP5)-ETA
scFv(225)-ETA
-O scFv(14E1)-ETA
Figure 5 Kinetics of scFv-ETA cell killing on A431 cells. The cells were
incubated with 100 ng ml-' of scFv(225)-ETA (0), scFv(14E1)-ETA (0) or
scFv(FRP5)-ETA (A) for various time intervals as indicated. After treatment,
the toxins were removed and the cells were incubated for another 40 h in
normal growth medium. The relative number of viable cells was determined
as described in Figure 3 and Materials and methods. Each point represents
the mean of a set of data determined in triplicate
toxin concentrations (IC50 3 ng m1') (Figure 4A). Very similar
results were obtained with MDA-MB468 cells (Figure 4B). TGF-
a-ETA and scFv(14El)-ETA displayed similar cell killing
activity with IC50 values ofapproximately 2 and 3 ng mll respec-
tively. ScFv(225)-ETA was also cytotoxic for MDA-MB468 cells
in a dose-dependent fashion but with a much higher IC50 value
of approximately 40 ng ml-'. The EGF receptor-specific anti-
body-toxins scFv(14E1)-ETA and scFv(225)-ETA at concentra-
tions of up to 1 gg ml-' did not display significant cell killing
activity on SKBR3 cells expressing high amounts of ErbB-2 but
only moderate levels of the EGF receptor (Figure 4C). In striking
contrast, the recombinant growth factor toxin TGF-a-ETA was
cytotoxic for SKBR3 cells atrelatively low concentrations with an
IC50 value of approximately 90 ng ml-' compared with an IC50 of
approximately 50 ng ml-' for the ErbB-2-specific antibody-toxin
scFv(FRP5)-ETA. Similar results were also obtained with T47D
human breast tumour cells which, like SKBR3 cells, express only
low levels ofthe EGF receptor. T47D cells were sensitive to TGF-
a-ETA (IC50 of 105 ng ml-') (Schmidt and Wels, 1996) but
highly resistant to scFv(14E1)-ETA and scFv(225)-ETA (IC50 >
1 jg ml-'; data not shown). The results show that scFv(14E1)-ETA
is highly cytotoxic for tumour cells overexpressing the EGF
receptor. Its activity is similar to that of TGF-a-ETA but much
more potent than that of scFv(225)-ETA. Importantly, both anti-
body-toxins, in contrast to the growth factor toxin, are highly
selective for EGF receptor-overexpressing cells.
EGFR_
Anti-EGFR
Figure 6 Inhibition of TGF-a-ETA-mediated activation of the EGF receptor
by scFv(14E1)-ETA and scFv(225)-ETA. A431 cells were treated with
1 gg ml-' of TGF-a-ETA in the absence of competitor (lane 1) or in the
presence of 50 ,g ml-1 scFv(14E1)-ETA (lane 4) or scFv(225)-ETA (lane 5).
Control cells were treated with PBS (lane 3) or with 20 ng ml-' EGF (lane 2).
Equal amounts of cell lysates were analysed by SDS-PAGE and
immunoblotting with an anti-phosphotyrosine MAb (upper panel) as
described in Figure 2. The amount of EGF receptor loaded in each lane was
analysed by reincubation of the filter with 12E EGF receptor-specific
antiserum (lower panel). The position of the 170-kDa EGF receptor is
indicated (EGFR). M, molecular weight standards
In order to analyse the kinetics of scFv-ETA binding to tumour
cells and scFv-ETA-mediated cell killing, a time course experi-
ment was carried out. A431 cells were treated for defined time
intervals with 100 ng ml-' each of scFv(14E1)-ETA and
scFv(225)-ETA. Control cells were treated with the ErbB-2-
specific scFv(FRP5)-ETA protein. Unbound scFv-ETA proteins
were removed and the cells were incubated in normal growth
medium for another 40 h. The relative number of viable cells was
determined as described above. The results are shown in Figure 5.
Potent cell killing was achieved after short incubation of the cells
with the EGF receptor-specific scFv-ETA proteins. While
maximal cell killing by scFv(14El)-ETA was already observed
after incubation for 2 min, a similar effect was achieved only after
incubation for 30 min with scFv(225)-ETA. In contrast, A431
cells had to be treated with the ErbB-2-specific scFv(FRP5)-ETA
for 100 min to achieve significant cell killing. Our data show that
A431 cell killing mediated by EGF receptor-specific scFv toxins
follows different kinetics than cell killing by the ErbB-2-specific
toxin. This might not only reflectthe approximately 50-fold differ-
ence in EGF receptor and ErbB-2 expression, which could allow a
more rapid binding of amounts of anti-EGF receptor toxins suffi-
cient for cell killing, but could also be due to differences in the
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Figure 7 Competition
of the cytotoxic activity of TGF-e ETA by scFv(225)
and scFv(14E1). MDA-MB468 (A), A431 (B) and SKBR3 cells (C) were
incubatedfor 40 h with 100 ng ml-' TGF-ca-ETA in the absence
of competitor
or in the presence
of 10 [tg ml-1 of scFv(225) or scFv(1 4E1I) as indicated. The
relative number
of viable cells was determined as described in Figure 3 and
Materials and methods. Each point was determined in triplicate. The standard
deviation is represented by error bars
internalization rates and intracellular pathways of EGF receptor
and ErbB-2. We have previously shown that A431 cells express
only moderate levels of ErbB-2 but are sensitive to
scFv(FRP5)-ETA, most likely because of autocrine activation of
ErbB-2-EGF receptor heterodimers (Wels et al, 1995). The much
faster cell killing by scFv( 1 4E 1)-ETA in comparison to
scFv(225)-ETA is likely due to the higher affinity of the former.
Differences in the internalization and the intracellular routing of
toxin-receptor complexes seem unlikely as both scFvs bind to an
identical or very similar epitope and do not induce receptor activa-
tion upon binding.
Inhibition of TGF-u-ETA binding by scFv proteins
Many human tumour cells that overexpress EGF receptors also
synthesize increased amounts of TGF- . which is transported to
the cell surface and activates EGF receptors in an autocrine
fashion (Derynck et al, 1987; Van de Vijver et al, 1991). This in
turn can lead to an increased growth response of the tumour cells.
The antagonistic MAb 225 displays growth-inhibitory activity on
tumour cells in vitro in the absence of active complement or
immune effector cells, suggesting that the antitumoral activity of
the antibody is mainly because of its ability to block EGF receptor
activation and to interrupt autocrine stimulation by TGF-ou (Ennis
et al, 1989). The very rapid cell killing effect observed after treat-
ment of tumour cells with scFv( 14E1)-ETA and scFv(225)-ETA
sug,ests that the inhibition of in vitro tumour cell growth by these
proteins is mainly due to their cytotoxic activity. Nevertheless, the
ability to interfere with TGF-o binding to the EGF receptor and
TGF-u-induced receptor activation might be an additional advan-
tage on autocrine-stimulated tumour cells. In order to test the
capacity of the scFv domains to block TGF-ox binding, competi-
tion experiments were performed.
A43 1 cells were treated for 10 min at 37°C with 500 ng ml of
TGF-oc-ETA with or without the addition of 50 ag ml of
scFv( 14E1)-ETA or scFv(225)-ETA as competitors. Control cells
were treated with PBS or 20 ng ml EGF. Equal amounts of cell
lysates were assayed for their phosphotyrosine content by SDS-
PAGE and subsequent immunoblotting with a specific anti-
phosphotyrosine antibody. The results are shown in Figure 6.
Treatment of cells with TGF-(x-ETA (lane 1) led to a strong
increase in the phosphotyrosine content of the EGF receptor
similar to treatment with EGF (lane 2). No TGF-a-ETA-induced
activation of the receptor was observed with scFv( 14E1)-ETA as a
competitor (lane 4), whereas scFv(225)-ETA, while also active as
a competitor, was unable to completely abolish EGF receptor acti-
vation (lane 5). PBS had no effect on the phosphotyrosine content
of the receptor (lane 3).
To analyse the competition of TGF-(x binding by scFv(14E1)
and scFv(225) in more detail, an experiment was carried out to
block the cytotoxic effect of TGF-a-ETA on several human
tumour cell lines by addition of scFv proteins lacking the toxin
domain. MDA-MB468, A431 and SKBR3 cells were incubated
for 40 h with100 ng ml-' of TGF-ax-ETA with or without the addi-
tion of 10 tg mll of scFv(14El) or scFv(225), and cell viability
was measured in comparison to PBS-treated cells as described
above. The results are shown in Figure 7. Both scFv proteins
potently inhibited TGF- a-ETA cytotoxicity on SKBR3 cells
expressing moderate levels of the EGF receptor. Without
competitor, approximately 56% of the cells were killed whereas, in
the presence of either scFv protein, cell killing was reduced to less
than10% (Figure 7C). On A431 cells overexpressing the EGF
receptor, cell killing was almost complete after incubation with
TGF-uETA (94% cell killing) (Figure7B). Addition of an excess
of scFv(225) hardly influenced the cytotoxic effect of TGF-
ax-ETA resulting in approximately 90% cell killing. In contrast,
scFv(14EI) was very potent in blocking the cytotoxic activity of
TGF-(x-ETA on A43 1 cells, reducing cell killing to approximately
28%. Similar results were obtained on MDA-MB468 cells (Figure
7A). TGF-ax-ETA treatment alone resulted in approximately 85%
cell killing, whereas the addition of scFv(225) or scFv(14EI)
reduced the cell killing by TGF-oc-ETA to approximately 63% or
15% respectively. The results show that scFv(14El) is a much
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more potent competitor ofTGF-a binding than scFv(225) and that
scFv(14E1) can protect cells from attack by TGF-a-ETA over a
prolonged period oftime.
DISCUSSION
EGFreceptorgeneamplification andoverexpressionhas been found
in many human tumours ofepithelial origin and has been correlated
with unfavourable patient prognosis (Gullick, 1991). Because ofits
involvement in the malignant process, its elevated expression in
tumours and its accessibility on the tumour cell surface, the EGF
receptor can be regarded as a potential target for directed tumour
therapy. Wehavepreviously characterized arecombinantantibody -
Pseudomonas exotoxin A fusion protein, scFv(225)-ETA, which
displayed antitumoral activity towards EGF receptor-overex-
pressing tumour cells but was less potent in tumour cell killing than
TGF-a-ETA, a recombinant toxin using the natural EGF receptor
ligand TGF-a as a targeting domain (Wels et al, 1995; Schmidt and
Wels, 1996). This prompted us to search for an alternative binding
domain that could mimic TGF-a in its efficiency to deliver a toxin
to tumour cells but, like the previously used scFv(225) domain, is
highly selective for EGF receptor- overexpressing cells, thereby
avoiding potential disadvantages of TGF-a-containing toxins,
such as cytotoxic activity on cells expressing moderate EGF
receptor levels. Here, we describe the construction and functional
characterization in vitro of a novel single-chain antibody-toxin,
scFv(14E1)-ETA, specific for the EGF receptor, which is based on
the independently isolated MAb 14E1.
Several criteria must be fulfilled for an anti-tumour fusion toxin
tobewell suitedfortargeting cells viaa surface molecule such as the
EGF receptor; the target-cell recognition domain must bind with
high affinity to its cognate receptor. Furthermore, highselectivity for
EGF receptor-overexpressing tumour cells is desired to minimize
unwanted side-effects on normal tissues that could express low
levels of the target antigen, and the cytotoxic domain of the anti-
tumour toxin should be catalytically active so that the molecule can
be effective at low concentrations. The scFv(14E1)-ETA protein
fulfils all these criteria. ScFv(14E1)-ETA binds to the EGFreceptor
with very high affinity, is highly cytotoxic towards EGF receptor-
overexpressing cells, while leaving other cells unaffected, and
furthermore exerts significant cell killing already after a very short
contact time between the antibody-toxin and the target cell.
ScFv(14El)-ETA displayed a nine times higher apparent affinity
than the similar scFv(225)-ETA, which binds to a very similar or
identical epitope. This high affinity of the scFv(14E1)-ETA seems
to be very important forits superior activity, as itis the only obvious
difference to scFv(225)-ETA and might account for the much
more potent cell killing activity of the former on EGF receptor-
overexpressing tumour cells.
In addition to their ability to deliver a cytotoxic effector to the
EGF receptor, both the scFv(225)-ETA and the scFv(14E1)-ETA
molecules harbour a functionally distinct activity: like the parental
MAb they competitively inhibit the binding of EGF and TGF-ac
to the EGF receptor, thereby blocking receptor activation. Over-
expression ofthe EGFreceptor in tumourcells is often accompanied
by increased production of the natural EGF receptor ligand TGF-a
(Derynck et al, 1987; Van de Vijver et al, 1991), which leads to
receptor activation by an autocrine pathway and contributes to
malignant transformation. Most likely, antagonistic MAbs directed
against the EGF receptor inhibit the growth of tumour cells
expressing both EGF receptor and TGF-a, primarily by abolishing
this autocrine growth signal (Ennis et al, 1989). Likewise, their
ability to compete TGF-a binding and receptor activation might
contribute to the antitumoral activity of the scFv(14El)-ETA and
scFv(225)-ETA proteins on tumour cells expressing EGF receptors
andTGF-a. Again, theability ofscFv(14E1)-ETA to competeTGF-
abinding was much morepronounced than thatofscFv(225)-ETA.
The antagonistic activity of scFv molecules could be used
directly to inhibit tumour cell growth in the absence of a cytotoxic
effector domain in a way very similar to the parental antibodies.
Because of their much smaller size, scFv proteins of approxi-
mately 27 kDa penetrate into solid tumours much fasterthan intact
MAbs (approximately 150 kDa) (Colcher et al, 1990). This could
be advantageous especially for tumourimaging with radiolabelled
compounds, when a rapid clearance of scFv molecules from the
circulation ofusually only several minutes is desirable but would
require repeated administration of high doses of scFv for thera-
peutic applications.
We have previously shown that the activity of recombinant
toxins targeted to members of the ErbB receptor family is depen-
dent on the expression level and also on the activation state and
turnover rate ofthe receptors (Wels et al, 1992b, 1995; Schmidt et
al, 1996). In contrast to the antibody-toxins, TGF-a-ETA has
growth factor activity and is able to activate EGF receptors upon
binding. In addition, TGF-ax-ETA is able to bind to heterodimers
of EGF receptor and ErbB-2 (Schmidt and Wels, 1996), which
might explain its activity on SKBR3 cells, which express low
levels of EGF receptor but in addition high levels of ErbB-2.
Activation ofreceptor homo- or heterodimers might translate into
more rapid internalization of receptor-toxin complexes, which
could lead to high cytotoxic activity against tumour cells. This
might also account, at least to some extent, for the severe toxicity
to normal tissues in animals after systemic administration ofhigh
doses ofTGF-a-PE40 (Pai etal, 1991), a molecule very similar to
TGF-a-ETA. One possible strategy to avoid the adverse side-
effects associated with growth factor toxins is the restriction to
local applications. In a recent clinical study with TGF-a-PE40
(TP40) in superficial bladder cancer, the molecule was applied
directly into the bladder by transurethral instillation and was well
toleratedby the patients (Goldberg et al, 1995).
It is surprising that scFv(14El)-ETA is almost as potent as
TGF-a-ETA in tumour cell killing, as the antibody-toxin cannot
activate the EGF receptor and is therefore limited to the passive
internalization ofthe target antigen to reach the cytosol, the site of
toxin activity. As, in contrast to TGF-a-containing toxins,
scFv(14El)-ETA lacks significant killing activity on cells
expressing low EGF receptor levels, it might be more tolerable
upon systemic administration and allow a broader range of thera-
peutic applications. ScFv(14El)-ETA was found to be apromising
and very potent novel antitumoral reagent in this in vitro study.
Our future experiments will be directed to analyse its tumour
growth-inhibiting activity in vivo.
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